Myriad Genetics, Inc.
MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Geā¦ read more
Healthcare
Diagnostics & Research
30 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.02
Price+5.60%
$0.16
1Y
Price
Market Cap
$285.234m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-20.4%
EBITDA Margin-22.6%
Net Profit Margin-5.4%
Free Cash Flow Margin-20.4%
EBITDA Margin-22.6%
Net Profit Margin-5.4%
Free Cash Flow MarginRevenue
$806.600m
-2.2%
1y CAGR+2.5%
3y CAGR+4.6%
5y CAGREarnings
-$112.600m
+69.2%
1y CAGR-22.2%
3y CAGR-50.4%
5y CAGREPS
-$1.19
+70.0%
1y CAGR-18.4%
3y CAGR-46.0%
5y CAGRBook Value
$303.900m
$638.900m
Assets$335m
Liabilities$210.500m
DebtDebt to Assets
33.0%
-3.6x
Debt to EBITDAFree Cash Flow
-$8.600m
+66.4%
1y CAGR+59.6%
3y CAGR+39.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company